Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical (NYSE: RBOT) has announced a strategic collaboration with UMass Memorial Medical Center, the largest not-for-profit hospital in Central Massachusetts. The partnership aims to support the adoption and utilization of Vicarious Surgical's robotic surgery system through various initiatives.
The collaboration will focus on streamlining operational aspects including inventory management, sterilization protocols, and standardization of pre and post-procedure processes. It will also encompass case observation for surgeons, system testing, research development insights, peer-to-peer education, and best practices promotion.
UMass Memorial Medical Center, with 826 licensed beds, serves as the clinical partner of the University of Massachusetts Chan Medical School and will work directly with Vicarious Surgical's team to refine and validate best practices in robotic surgery.
Vicarious Surgical (NYSE: RBOT) has announced its upcoming first quarter 2025 financial results release, scheduled for May 12, 2025, after market close. The company, which specializes in next-generation robotics technology for surgical applications, will discuss its financial performance for the period ending March 31, 2025.
Key Details:
- Conference Call Time: 4:30 p.m. Eastern Time
- Dial-in Numbers: - Domestic: +1 833-470-1428 - International: +1 404-975-4839
- Access Code: 316641
Investors and interested parties can access the live and archived webcast of the event through the company's investor relations website at investor.vicarioussurgical.com. The company's mission focuses on improving lives through the transformation of robotic surgery.
Vicarious Surgical (NYSE: RBOT) has received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards. The company failed to maintain both a 30-day average market capitalization and stockholders' equity above $50 million, with market cap averaging approximately $47.4 million.
The company has 45 days to submit a compliance plan to the NYSE, detailing actions to meet requirements within an 18-month cure period. During this time, RBOT stock will continue trading with a '.BC' (below criteria) designation. If the plan is not submitted timely or accepted, NYSE will initiate delisting proceedings.
The notice does not affect daily operations or SEC reporting obligations. The company is evaluating options to regain compliance with NYSE listing standards.
Vicarious Surgical (NYSE: RBOT) announced that Company President Randy Clark will transition to a Board Member role, effective April 25, 2025. As President, Clark led key business functions including product development, operations, clinical regulatory, quality affairs, and human resources.
During his tenure, Clark made significant contributions by:
- Developing manufacturing capabilities and strengthening supply chain
- Establishing key partnerships
- Implementing personnel realignment
- Streamlining business processes
- Formalizing workflows and standardizing procedures
CEO Adam Sachs acknowledged Clark's role in building a strong foundation for future growth. Clark will continue to provide strategic guidance as a Board member, ensuring his expertise remains available to the company while allowing for leadership evolution aligned with strategic and capital needs.
Vicarious Surgical (NYSE: RBOT) has reported its Q4 and full year 2024 financial results, marking significant progress with the completion of Version 1.0 System integration. The company expanded strategic partnerships with LSU Health New Orleans, Temple Health, and University of Illinois Health, while preparing for first clinical use in 2025.
Financial highlights for Q4 2024 include operating expenses of $15.0 million (down 3% YoY), with a GAAP net loss of $13.9 million ($2.36 per share). Full year 2024 saw operating expenses of $66.6 million (17% decrease YoY) and a GAAP net loss of $63.2 million ($10.74 per share).
The company ended 2024 with $49.1 million in cash and investments, achieving its 2024 cash burn guidance. For 2025, Vicarious Surgical has set a cash burn guidance of approximately $50 million. The company has appointed Sarah Romano as CFO, effective April 1st, 2025.
Vicarious Surgical (NYSE: RBOT) has appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano brings decades of financial leadership experience in capital markets, particularly in the healthcare sector. She previously served as CFO of Entero Therapeutics, where she managed financial strategy and executed product in-licensing partnerships.
At her former position as CFO of Kiora Pharmaceuticals, Romano secured over $50 million in funding and led M&A activities. Her expertise includes financial strategy, operations, compliance, budget reviews, forecasting, internal controls oversight, and SEC reporting. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 17, 2025, after market close. The robotics technology company, focused on advancing robotic surgery, will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Investors can participate in the conference call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) with access code 373279. A webcast will be available live and archived at the company's investor relations website.
Vicarious Surgical (NYSE: RBOT) announced that Chief Operating Officer John Mazzola will retire effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain, and quality control. Mazzola's responsibilities will transition to Company President Randy Clark.
According to CEO Adam Sachs, Mazzola has been key in developing manufacturing processes, enhancing product quality control, and strengthening supply chain resilience. The company states it is well-positioned for its next phase, including upcoming first clinical use cases and pivotal trial.
Vicarious Surgical (NYSE: RBOT) announced that Chief Financial Officer William Kelly will be departing the company on January 2, 2025. Kelly, who has served as CFO since January 2021, is leaving to pursue other career opportunities after nearly four years with the company.
Kelly will assist in ensuring a smooth transition of responsibilities before his departure. The company has initiated a CFO succession process and will provide updates accordingly. CEO Adam Sachs expressed gratitude for Kelly's significant contributions during his tenure.
Vicarious Surgical announced its Q3 2024 financial results. Operating expenses decreased by 17% to $17.8M from $21.4M in Q3 2023. R&D expenses dropped to $10.8M from $13.0M, general and administrative expenses fell to $5.7M from $6.9M, and sales and marketing expenses decreased to $1.2M from $1.4M. The adjusted net loss was $17.0M, or $2.87 per share, compared to $20.4M, or $3.95 per share, in the same period last year. GAAP net loss was $17.1M, or $2.90 per share, versus $15.7M, or $3.04 per share, last year. The company had $60.9M in cash and investments as of September 30, 2024, with a Q3 cash burn rate of $12.4M. Full-year 2024 cash burn is expected to be approximately $50M. CEO Adam Sachs highlighted the upcoming milestone for the Version 1.0 System integration and the goal to complete the first clinical patient within a year.